Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center — Atlanta, Georgia

Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center is a clinical research site located in Atlanta, Georgia, United States 30322.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center has participated in 1 clinical trials.

Therapeutic areas: Healthy, Sickle Cell Anemia.

Sponsors: Pfizer.

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center?

Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center conducted?

Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center has 1 clinical trials on record. Their work covers Healthy, Sickle Cell Anemia.

Is Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center accredited by Crixeo Health?

Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.